Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlycoMimetics Inc (NASDAQ:GLYC)

7.05
Delayed Data
As of Aug 28
 -0.03 / -0.42%
Today’s Change
6.18
Today|||52-Week Range
9.68
-2.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$134.7M

Company Description

GlycoMimetics, Inc. is a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Gaithersburg, MD.

Contact Information

GlycoMimetics, Inc.
401 Professional Drive
Gaithersburg Maryland 20879
P:(240) 243-1201
Investor Relations:
(240) 243-1207

Employees

Shareholders

Individual stakeholders51.69%
Other institutional14.61%
Mutual fund holders14.60%

Top Executives

Rachel K. KingPresident, Chief Executive Officer & Director
Brian M. HahnChief Financial Officer & Head-Media Relations
John L. MagnaniSecretary, Director, Chief Scientific Officer & VP
Helen M. ThackrayChief Medical Officer & VP-Clinical Development
Armand GirardVice President-Corporate Development